Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
13.81% 10.52% 10.68% 9.42%
ROA
10.42% 8.03% 8.32% 7.35%
ROIC
12.80% 11.78% 11.60% 12.81%
Return on Tangible Assets
21.00% 15.93% 16.50% 14.05%
Average Days of Receivables
55.38 54.87 56.34 53.56
Free Cash Flow per Share
1.38 2.28 1.88 2.49
Free Cash Flow
804.20 1,335.00 1,089.50 1,433.60
Other line items

Show all line items

Columns are period end dates